9 Meters Biopharma, Inc. (NMTR)
|Net Income (ttm)||-65.44M|
|Trading Day||March 5|
|Day's Range||1.20 - 1.43|
|52-Week Range||0.37 - 2.26|
RALEIGH, NC / ACCESSWIRE / March 1, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, announced today the Company has appoi...
9 Meters Biopharma (NMTR) has moved higher as of late, but there could definitely be trouble on the horizon for this company.
While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
NMTR stock is on the move Wednesday. Here's what you should know about 9 Meters Biopharma, which specializes in GI conditions.
9 Meters Biopharma Announces Agreement with the European Biomedical Research Institute of Salerno (EBRIS) to Continue Evaluation of Larazotide for COVID-19 Respiratory Complications
Larazotide, a novel tight junction modulator, has shown positive effect in multiple lung models of acute respiratory distress, acute lung injury, and pulmonary fibrosis with potential effects ...
9 Meters Biopharma (NMTR) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Investors need to pay close attention to 9 Meters Biopharma (NMTR) stock based on the movements in the options market lately.
9 Meters Biopharma (NMTR) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Shares of 9 Meters Biopharma Inc (NASDAQ: NMTR) were ripping higher following a bullish initiation by Brookline Capital Markets.
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating 9 Meters Biopharma, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
NEW YORK, July 13, 2020 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiducia...
9 Meters Biopharma Inc. (NASDAQ: NMTR) may not be a household name right now, but one brokerage firm sees huge potential upside.
9 Meters Biopharma, a clinical-stage biotechnology company, focuses on patients with rare disorders and unmet needs. The company's pipeline includes drug candidates for short bowel syndrome (SBS) and celiac disease. It is developing NM-002, a long-acting injectable GLP-1 agonist that is in a Phase 2 clinical trial for SBS; and Larazotide, a Phase 3-stage therapeutic in development for celiac disease. The company also develops NM-003, a proprietary long-acting GLP-2 agonist; and NM-004, a double-cleaved mesalamine with an immunomodulator for dev... [Read more...]
|Stock Exchange |
|Ticker Symbol |